Hints and tips:
Related Special Reports
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...According to Israeli health minister Nitzan Horowitz, a booster would be made available to adults who are suffering from severe immunodeficiency, have undergone a recent organ transplant, or are generally...
...Three weeks after receiving a first dose of the BioNTech/Pfizer vaccine, sufficient antibody levels to combat the virus were detected in 39 per cent of patients with organ cancer and 13 per cent of those...
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Mr Kulkarni said the sector would become more like “Apple v Samsung”, where biotechs competed on adding generation after generation of features....
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...US-based Pfizer last year recognised this new landscape by establishing a division to bring together health economists; researchers measuring the outcomes produced by different medicines; and market access...
...Analysts suggest the fall in Bristol-Myers’ value has turned it into a takeover target, most likely for Pfizer or Novartis ....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Better to die of cancer, he said, than a slow decline from organ failure or dementia....
...organs....
...When the machines are able to build organic proteins it will be able to build hamburgers or beefsteaks or perhaps even human organs for transplant. It will come into its own, but perhaps not yet....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...The case (now called FCC v. Fox Television Stations et al) was appealed to the US Supreme Court, where it was debated on Tuesday....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Joe Jimenez, head of pharma at Novartis, says he has seen poor drugs compliance for chronic conditions and even organ transplants....
...In this respect, organisations such as the GBC can play a convening role....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...Infamously, they see no difference between the New York Times and Pravda, formerly the organ of the Central Committee of the Soviet Communist Party....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...The US-based company, which will set up a similar facility in Massachusetts, aims to “develop a new generation of regenerative medicines …that may prevent disability, repair failing organs and treat degenerative...
...There have been many complaints over the years but the 1996 Shetland Times v Shetland News case sticks in the memory....
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
International Edition